Anti-Competitive Strategy Around Brand Name Narcolepsy Medications Blocked Patients from Accessing Alternatives In case you missed it, on Tuesday, The New York Times reported on anti-competitive tactics used by Jazz Pharmaceuticals on their brand name narcolepsy drugs, Xyrem and Xyvaw, to block patients from accessing alternatives — including alternatives that may be more effective. The […]
Big Pharma Giants Once Again Top Wall Street Expectations in Final Round of Fourth Quarter Earnings Reports While Continuing to Price-Gouge American Patients A final round of Big Pharma 2022 fourth-quarter earnings reports from AbbVie and AstraZeneca showcases the pharmaceutical industry continues to ride high on blockbuster profits, fueled by price hikes and egregious anti-competitive […]
Four Big Pharma Giants That Hiked Drug Prices on American Patients in 2022 and First Weeks of 2023 All Beat Wall Street Earnings Expectations Another round of fourth-quarter earnings reports from Merck, Sanofi, Bristol-Myers Squibb and Eli Lilly show that brand-name drug manufacturers continue to rake in blockbuster profits while price-gouging the American people. All […]
Lawmakers Should Focus Attention on Brand Name Drug Companies That Set Prices, Increase Prices and Game the System to Block Competition Lawmakers must remember that Big Pharma is the culprit behind out-of-control prescription drug prices, and the sole entity responsible for setting and hiking prescription drug prices — and should reject Big Pharma’s multi-million-dollar blame […]
Senate Judiciary Committee Advances Bipartisan Legislation Cracking Down on Big Pharma’s Patent Abuse Last week, the U.S. Senate Committee on the Judiciary advanced the Affordable Prescriptions for Patients Act of 2023 to the full Senate for consideration. The legislation, introduced by Senator John Cornyn (R-TX) and Senator Richard Blumenthal (D-CT), advances solutions to hold Big […]
Brand Name Drug Companies Kick Off Q4 Earnings Calls After More than 600 Price Hikes to Start 2023 Last week, Pfizer, Amgen, GlaxoSmithKline, Novartis, and Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the final quarter of 2022. Each of the Big Pharma giants surpassed Wall Street analysts’ earnings […]
Critical Legislation Targets Anti-Competitive Practices like Patent Thickets and Product-Hopping That Cost Patients and the U.S. Health System Billions of Dollars Today, the U.S. Senate Committee on the Judiciary is scheduled to consider legislation that would crack down on Big Pharma’s egregious anti-competitive tactics that block competition from more affordable alternatives. Introduced by Senators John […]
Non-Profit Advocates for Affordable Prescription Drug Prices Call on Congress to Increase Competition and Hold Big Pharma Accountable In case you missed it, Tahir Amin and Priti Krishtel, co-executive directors of the Initiative for Medicines, Access & Knowledge (I-MAK), published an op-ed in The Hill calling on Congress to lower prescription drug prices by holding […]
New Matrix Global Advisors Report Shines Light on Cost of Big Pharma’s Patent Abuse A new report released on Thursday by Matrix Global Advisors and commissioned by the Coalition for Affordable Prescription Drugs, “Patent Thickets and Lost Drug Savings,” examines the cost of Big Pharma’s use of ‘patent thickets’ on patients and the U.S. healthcare […]
Analysis Finds Drug Companies Increased Prices Faster Than the Rate of Inflation on 70 of the 93 Best-Selling Part B Prescription Drugs In case you missed it, researchers affiliated with Brigham and Women’s Hospital and Harvard University published an analysis in The Journal of the American Medical Association (JAMA) which found that the Medicare Part B program […]